VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. - Wikidata - awgldk - TriplyDB

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

http://www.wikidata.org/entity/Q33937644

about

Non-invasive approaches to monitor EGFR-TKI treatment in non-small-cell lung cancer A novel classification of lung cancer into molecular subtypes Molecular pathways and therapeutic targets in lung cancer Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.EGFR-mutated lung cancer: a paradigm of molecular oncology.Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.QiShenYiQi Pills, a Compound Chinese Medicine, Ameliorates Doxorubicin-Induced Myocardial Structure Damage and Cardiac Dysfunction in Rats Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.The Evolving Role of Maintenance Therapy Using Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) in the Management of Advanced Non-Small-Cell Lung Cancer.VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer and Impaired Performance Status as Selected by a Serum Proteomics Assay.Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).Personalized medicine for lung cancer: new challenges for pathology.Proteomic biomarkers in lung cancer.Current clinical application of genomic and proteomic profiling in non-small-cell lung cancer.Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis.Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.Prognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.The value of proteomics in lung cancer.Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.

P2860

Q26801357-EF9E8202-0F8C-4B23-A907-F7D0AC22AEBB Q28731874-D34EF6DA-A35F-43C8-B11F-1FF49D51A990 Q33688872-7AB40782-E3E8-4AAE-854F-7590B1264749 Q33778668-FBB3720A-7E32-46E2-BE67-B29D24565854 Q34406334-164BFB60-FE05-489B-9018-15E8D13E6B94 Q34443983-18720064-6512-45D6-B2DE-D12E56DB8F33 Q34637521-57B9A67B-7577-4AE1-8660-B982234871DD Q35034044-FB174000-3EC9-40AD-B4E1-0EA6E851C3D8 Q35081379-5F467B84-0BC5-4781-94B8-8A444FEF3D60 Q35108419-1B8F6862-8AD9-4710-8E13-E03E0F2CA48C Q35238008-F01909EF-5192-43AA-B115-D111204FCE32 Q35835931-E339F3C8-328A-443A-BE5A-F5876AA3A11E Q36419366-A09AFAF3-90AA-476F-99C5-C4CA43AE82B7 Q36642739-B772D734-AA3E-4E1F-82AC-ACA9BF634C73 Q37329315-53B0F1B9-2272-4C26-AADA-D1C2D3BFC772 Q37932029-137DD3B9-C2A3-47B5-A8D1-7CE01B906461 Q38100750-72E6EF15-93BF-4C03-AD5E-3DB781C81A02 Q38172914-B8C48182-9C72-44C7-923A-3469B7EC19EF Q38765422-C32090E4-A4E2-49C5-AD0A-A2B0AC3B313A Q38882266-33814BC9-12D6-4D3A-AB81-1898345A0F97 Q40451221-D58CE597-BE9A-4205-8AFB-04E36F2CA468 Q41670014-4BD91C65-EFD4-4980-BBEF-FAEA91C2CFE2 Q43183700-E9ADD6AD-55A1-468D-8636-20674AA60DDC Q45072735-69366233-CD70-4DDF-ADCA-E6846E39BA4D Q52646495-F4939C57-EDB9-4352-8C0B-9361BD4B5762

P2860

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

http://www.wikidata.org/entity/Q33937644

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

VeriStrat classifier for survi ...... ith erlotinib and bevacizumab.

@ast

VeriStrat classifier for survi ...... ith erlotinib and bevacizumab.

@en

type

label

VeriStrat classifier for survi ...... ith erlotinib and bevacizumab.

@ast

VeriStrat classifier for survi ...... ith erlotinib and bevacizumab.

@en

prefLabel

VeriStrat classifier for survi ...... ith erlotinib and bevacizumab.

@ast

VeriStrat classifier for survi ...... ith erlotinib and bevacizumab.

@en

P1433

Q33937644-296B7262-6133-48DD-84DD-237046F6F29F

P1476

Q33937644-32A0F0E2-2B87-4AC6-9B86-46AFDBABC1AE

P2093

Q33937644-1964E119-FE49-4058-9639-0B2F34F29504

Q33937644-29EFEEB4-A2D8-4A8A-AA5C-894D543A7D38

Q33937644-54245640-A59A-4BF5-8A76-66F4FAA3380F

Q33937644-646C4E17-E9A0-474B-BBB0-AD4D0F9114B4

Q33937644-8A009B15-7CB0-47EF-A455-E5C3ED732F2F

Q33937644-9B3B014C-DF36-4EDD-98E6-F79304D00212

Q33937644-B6257EC2-E366-480E-AAB1-173727844A11

Q33937644-D55EE951-0065-41F8-BB8E-847CAAB8FB74

Q33937644-DE6C729C-35A8-49E4-8538-ACB6EB1A6B10

Q33937644-E5B4D57A-9AC3-4919-904A-F79411CA2895

P2860

Q33937644-332FF6C4-5C6C-4054-B0AA-E6421B69386D

Q33937644-34950CFD-A659-4FE3-B659-62BE2203752D

Q33937644-40415ABB-BD1C-426F-BCD9-31F595E30E59

Q33937644-8341DB67-1196-4271-B373-D28D02205D5E

Q33937644-C2AE74A4-BE3D-4802-866E-72C277C54881

Q33937644-CC7B3848-07BA-4C4F-A120-294F07637433

Q33937644-CFE05DAC-710B-4558-BC3F-9628C86E739A

Q33937644-DBA69E9E-7EBC-45A7-AA37-12CA9321A53B

Q33937644-F0224DF2-6C9D-45C6-9F5C-DD3317A0D5C1

P304

Q33937644-1C8F7497-EE2F-4D0F-80CD-02DEC5C4C741

P31

Q33937644-0412981E-1593-4E1D-AA89-07F23EA46708

P356

Q33937644-36BE89F8-69FB-4B05-B832-D10D0D66D060

P433

Q33937644-0CE57D5F-CDA0-439D-9FB3-79D97E7460E5

P478

Q33937644-61CDC0E6-63E3-4A9E-8042-636C1942244D

P50

Q33937644-577D4161-6632-488C-A4BF-8F200551152D

P577

Q33937644-9DA48F9A-0289-4114-B34E-BA82BDEF4E86

P5875

Q33937644-7FBE2225-E020-473C-8298-25DB2D226881

P698

Q33937644-8F35B13E-2BF7-4918-BCC3-BB10CF6A1186

P921

Q33937644-A96C2C97-43CA-4FFF-BC4F-36C22D2C6608

P932

Q33937644-1F48FDFC-421B-45B8-80B9-77E8F3B0D910

P356

J.LUNGCAN.2009.11.019

P1433

P1476

VeriStrat classifier for survi ...... ith erlotinib and bevacizumab.

@en

P2093

Alan Sandler

http://www.w3.org/2001/XMLSchema#string

Anne S Tsao

http://www.w3.org/2001/XMLSchema#string

David P Carbone

http://www.w3.org/2001/XMLSchema#string

Dean Billheimer

http://www.w3.org/2001/XMLSchema#string

Hai T Tran

http://www.w3.org/2001/XMLSchema#string

Heidi Chen

http://www.w3.org/2001/XMLSchema#string

Heinrich Roder

http://www.w3.org/2001/XMLSchema#string

J Stuart Salmon

http://www.w3.org/2001/XMLSchema#string

Joanna Roder

http://www.w3.org/2001/XMLSchema#string

Maxim Tsypin

http://www.w3.org/2001/XMLSchema#string

P2860

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Erlotinib in previously treated non-small-cell lung cancer

Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.

Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.

Angiogenesis and lung cancer: prognostic and therapeutic implications.

Bevacizumab in the treatment of non-small-cell lung cancer.

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.

Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.

P304

337-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.LUNGCAN.2009.11.019

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40785194

http://www.w3.org/2001/XMLSchema#string

P698

20036440

http://www.w3.org/2001/XMLSchema#string

P921

P932

2891357

http://www.w3.org/2001/XMLSchema#string